Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACCShell Companies
+$0.00 today
- Market cap
- $263.53M
- Beta
- -0.04
- P/E (TTM)
- 29.1
- EPS (TTM)
- $0.37
Volume 0.00M
Average 0.01M
OACC Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Oaktree Acquisition Corp. III Life SciencesNASDAQ: OACC
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow of -$158.04K in Q1 FY2026
Q1 FY2026 free cash flow was -$158.04K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (422.08K) USD
- Year-over-year change
- -235698.3%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (422.08K) | -235698.3% |
| FY2024 | 2024-12-31 | (179) | — |
Free Cash Flow vs competitors
How OACC compares with its peers on the latest reported figures
- OACC's FY2025 free cash flow of $422.08K is the 9th largest of the 10 companies compared; the peer median is $840.84K.
- Its year-over-year change of +235698.3% is the highest of 4, against a peer median of +466.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.58M | — | — | — | |
MBAVM3-Brigade Acquisition V Corp. Class A Ordinary shares | LTM Mar 2026 | $2.86M | +466.2% | — | — |
| FY2025 | $930.71K | +482.2% | -12.5% | — | |
AACBArtius II Acquisition Inc. Class A Ordinary Shares | FY2025 | $842.15K | — | — | — |
| LTM Mar 2026 | $840.84K | — | — | — | |
| LTM Mar 2026 | $809.12K | +165.9% | -14.2% | — | |
| LTM Sep 2025 | $673.16K | — | — | — | |
| FY2025 | $504.5K | — | — | — | |
OACCOaktree Acquisition Corp. III Life Sciences | FY2025 | $422.08K | +235698.3% | — | — |
COPLCopley Acquisition Corp | LTM Mar 2026 | $123.64K | — | — | — |
| Peer median (excluding OACC) | $840.84K | +466.2% | -13.3% | — | |
Competitors are the stored peer set for OACC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | 2.66K | 7.29M |
| Depreciation & Amortization | 0 | 0 |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | (629) | 0 |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 0 | (33.55K) |
| Other Working Capital | (629) | 0 |
| Other Non-Cash Items | (91.72K) | (7.71M) |
| Operating Cash Flow | (179) | (422.08K) |
| Capital Expenditures | (3) | 0 |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (191.99M) | 0 |
| Sales of Investments | 0 | 0 |
| Other Investing Activities | 0 | 500K |
| Investing Cash Flow | (191.99M) | 500K |
| Debt Repayment | (551.14K) | 0 |
| Common Stock Issued | 193.99M | 0 |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 0 | 0 |
| Financing Cash Flow | 193.44M | 0 |
| Effect of Forex Changes | 0 | 0 |
| Net Change in Cash | 1.36M | 77.92K |
| Free Cash Flow | (179) | (422.08K) |
Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACC
Intrinsic Alpha fair value
Locked
Current Price
$10.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.